H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV (IMV) on July 14 and set a price target of $13.00. The company’s shares closed last Tuesday at $5.51.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 33.0% and a 56.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IMV with a $7.41 average price target, representing a 25.6% upside. In a report issued on July 14, Wells Fargo also maintained a Buy rating on the stock with a $11.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.82 and a one-year low of $1.35. Currently, IMV has an average volume of 1.45M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm’s candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck’s Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.
Read More on IMV:
